NCT07189949

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

A Phase I Study of HRS-2329 Evaluating Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.

Conditions

• Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Interventions

Type	Name	Description
DRUG	HRS-2329 Tablet	Oral HRS-2329 tablet.

Timeline

• Start date: 2025-10-16
• Primary completion: 2028-12-01
• Completion: 2028-12-01
• First posted: 2025-09-24
• Last updated: 2026-03-06

Locations

1 site across 1 country: China